Brief: Scancell Holdings Receives FDA Fast Track Designation For iSCIB1+ In Advanced Melanoma
28/04/2026 07:35
April 28 (Reuters) - Scancell Holdings PLC SCLP.L: SCANCELL HOLDINGS - FDA FAST TRACK DESIGNATION FOR ISCIB1+ SCANCELL HOLDINGS PLC - RECEIVES FDA FAST TRACK DESIGNATION FOR ISCIB1+ IN ADVANCED MELANOMA SCANCELL HOLDINGS PLC - PHASE 3 TRIAL WITH ISCIB1+ IN ADVANCED MELANOMA ANTICIPATED IN H2 2026 Source text: ID:nRSb1041Ca Further company coverage: SCLP.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scancell Holdings
See all newsBrief: Scancell Holdings Receives FDA Fast Track Designation For iSCIB1+ In Advanced Melanoma
Brief: Scancell Holdings Appoints David Schilansky As Financial Advisor And Interim CFO
Scancell Holdings - Scancell announces CFO transition
Brief: Scancell To Explore Partnering Opportunities For Moditope Following New Modi-1 Phase 2 Data
Scancell Holdings - Half-year Financial Report